Cryo-Save Group N.V.: Director/PDMR Shareholding

Cryo-Save Group N.V.: Director/PDMR Shareholding

ID: 49008

(Thomson Reuters ONE) -


Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), Europe's
leading adult stem cell storage bank, has been informed today that Mr Marc
Waeterschoot, Executive Director, purchased 20,000 ordinary shares of Euro 0.10
('Ordinary Shares') at a price of ?5.10 on 18 November  2010. Following this
purchase, Marc Waeterschoot is beneficially interested in 1,853,850 ordinary
shares, representing approximately 19.84% of the Group's issued share capital.

The Group has also been informed today that Mr Arnoud van Tulder, Chief
Executive Officer, purchased 2,000 ordinary shares of Euro 0.10 ('Ordinary
Shares') at a price range between ?4.95 and ?5.15 between 18 November 2010 and
22 November 2010. Following this purchase, Arnoud van Tulder is beneficially
interested in 15,000 ordinary shares, representing approximately 0.16% of the
Group's issued share capital.



Enquiries:

Cryo-Save Group + 31 (0) 575 548 998

Arnoud van Tulder, Chief Executive Officer

SPJ Financiële Communicatie (The Netherlands) +31 (0)20 6478181

Kees Jongsma/Leon Melens

Daniel Stewart & Company plc (UK) + 44 (0) 20 7776 6550

Chris Theis

College Hill (UK) + 44 (0) 20 7457 2020

Rozi Morris/ Adrian Duffield



Free footage is available on www.videobankonline.com.

About Cryo-Save

With more than 141,000 samples saved, Cryo-Save is the leading stem cell bank in
Europe and one of the fastest growing in the world. Driven by its international
business strategy, Cryo-Save is now represented in 40 countries on three
continents with state-of-the-art processing facilities in Belgium, Germany,
Dubai, India and France.



[HUG#1464590]





Click here for full press release in PDF:
http://hugin.info/143308/R/1464590/403003.pdf








This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE


Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Carlo Gavazzi: improvement of all key figures Basilea initiates phase I clinical program of its novel antibiotic BAL30072
Bereitgestellt von Benutzer: hugin
Datum: 23.11.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 49008
Anzahl Zeichen: 2599

contact information:
Town:

Zutphen



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 191 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cryo-Save Group N.V.: Director/PDMR Shareholding"
steht unter der journalistisch-redaktionellen Verantwortung von

Cryo-Save Group N.V. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cryo-Save Group N.V.



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z